Kingdon Capital Management is a New York-based alternative investment firm founded in 1983. The firm provides global investment services to high net worth individuals and institutional clients, focusing on public equity, fixed income, and alternative markets. Kingdon employs a top-down approach, investing in growth and value stocks across all market capitalizations.
The firm's portfolio includes investments in biotech and healthcare companies such as Athenex, enVVeno Medical, Sapience Therapeutics, Shoreline Biosciences, and Stealth BioTherapeutics. Kingdon typically participates in Series B and Post-IPO Equity rounds, with occasional involvement in Convertible Note financing. As a registered investment adviser regulated by the SEC, Kingdon offers sophisticated investment strategies and risk hedging services to its clients.
Kingdon Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies5
Current Portfolio Count5
Top Investment Stages
Series B2 (100.0%)
Stage Mix
Series B 100%
Concentration shown as share of disclosed investments by stage.
Kingdon Capital Management is a NYC-based hedge fund sponsor, offering global investment services and risk hedging to high net worth clients since 1983.
